Key terms
About IMTX
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IMTX news
Mar 29
4:26am ET
Maintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising Partnerships
Mar 24
9:50pm ET
Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)
Mar 21
8:57am ET
Immatics N.V. Showcases Clinical Strides and Fiscal Health
Mar 21
7:11am ET
Immatics sees cash runway into 2027
Mar 21
7:10am ET
Immatics reports 2023 EPS (EUR 1.20) vs. EUR 0.55 last year
Mar 06
11:59pm ET
Buy Rating Affirmed for Immatics on Promising TCR-Based Cancer Therapies and Strategic Partnerships
Jan 17
8:36pm ET
Immatics 15.925M share Spot Secondary priced at $11.00
Jan 17
4:04pm ET
Immatics announces ordinary shares offering, no amount given
No recent press releases are available for IMTX
IMTX Financials
Key terms
Ad Feedback
IMTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IMTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
